Evidence map›Paper›PMID 32346296›Full record

ArticleOncoTargets and therapy2020

Lamin B1 Overexpresses in Lung Adenocarcinoma and Promotes Proliferation in Lung Cancer Cells via AKT Pathway.

Wei Li, Xiaoqing Li, Xiaoping Li, Mingjiang Li, Pan Yang, Xuhui Wang, Lei Li, Bo Yang

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Prognostic Significance ofInternational journal of molecular sciences · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. LMNB1, a potential marker for early prostate cancer progression.American journal of cancer research · 2022
    Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wei Li *Department of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Xiaoqing Li *Phase I Clinical Trial Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Centre for Cancer, Tianjin 300052, People's Republic of China.ORCID 0000-0001-6489-198X
Xiaoping LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Mingjiang LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Pan YangDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Xuhui WangDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Lei LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Bo YangDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin 300192, People's Republic of China.
Tianjin First Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to investigate the biological effect and molecular mechanism of Lamin B1(LMNB1) in lung cancer cells and its significance for the prognosis of lung adenocarcinoma(LUAD) patients.

methodsIn this study, Bioinformatics was performed to analyze the expression at mRNA level and prognosis effect of LMNB1 in LUAD from TCGA dataset. The immunohistochemistry(IHC) assay was conducted to analyzed the expression of LMNB1 at the protein level in LUAD tissues. The correlation between the expression of LMNB1 and the clinical factors in patients with LUAD was analyzed. Next, LMNB1 transfected into LUAD cell lines (A549 and PC-9) which was proved by Western blot. CCK8 assay, cloning formation assay, and xenograft assay were conducted to explore the effect and mechanism of LMNB1 on the proliferation of LUAD cell lines in vitro and in vivo.

resultsThe results of the present study demonstrated that LMNB1 was highly expressed in LUAD tissues and related to tumor stage. High LMNB1 expression was related with more advanced clinicopathological factors such as low degree of differentiation (P=0.02), large tumor size (P<0.01), lymph node metastasis (P<0.01) and higher tumor stage (P<0.01). After knocking down LMNB1, the cell growth rate (P<0.01) and the number of colonies (P<0.01) were significantly reduced, and the level of the proliferating marker Ki67 (P<0.01) was significantly decreased. At the same time, in vivo experiments showed that the tumor volume and tumor of the mice were significantly reduced (P<0.01). Moreover, we found that knockdown LMNB1 can inhibit the proliferation of lung cancer cells by inhibiting AKT phosphorylation by Western blot.

conclusionIn summary, LMNB1 play an of vital roles in the growth of LUAD cells, highlighting its potential as a therapeutic target for the treatment of LUAD patients.

Indexed as

lamin B1lung adenocarcinomamalignant behaviorprognosis

Identifiers

PMID32346296
PMCPMC7167283
OpenAlexW3017062441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.